A. J. Grillo-Lopez, MD

Articles

The impact of anticancer therapy on quality of life has been receiving increasing attention, particularly with diseases such as low-grade non-Hodgkin’s lymphoma (NHL), where palliation rather than cure is the primary objective of therapy. The

Ibritumomab Tiuxetan Radioimmunotherapy Improves Quality of Life in Patients With Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma

Rituximab (Rituxan) is a chimeric monoclonal antibody that targets the CD20 anti-gen on normal and malignant non-Hodgkin’s lymphoma (NHL) cells. It has been shown to produce immediate, severe, and specific B-cell depletion in

Peripheral Blood B-Cell Recovery in Patients With Non-Hodgkin’s Lymphoma Treated With Rituximab Does Not Correlate With Onset of Disease Progression

Treatment of low-grade or follicular non-Hodgkin’s lymphoma (NHL) is associated with a high rate of initial response, followed invariably by relapse. Subsequent remissions occur at a progressively lower rate and with progressively shorter

Rituximab: Sustained Remissions in Patients With Relapsed or Refractory Low-Grade or Follicular Non-Hodgkin’s Lymphoma

Possible mechanisms of action of the chimeric CD20 monoclonal antibody rituximab (Rituxan) involve complement- and antibody-dependent cellular cytotoxicity (ADCC). Because granulocyte colony-stimulating factor (G-CSF [Neupogen])

Treatment of Relapsed B-Cell Non-Hodgkin’s Lymphoma With a Combination of Chimeric Anti-CD20 Monoclonal Antibodies (Rituximab) and G-CSF: Final Report on Safety and Efficacy

Author | A. J. Grillo-Lopez, MD

Articles

New content coming soon, please check back later.